Table 4.
Prevalence of CYP2B6 genotypes and predicted phenotypes in 51 HIV-infected patients stratified by the reasons of testing
| Reasons and results |
CYP2B6 polymorphisms
|
|||
|---|---|---|---|---|
| No mutation | 18492T>C | 21563C>T | Other | |
| Screening (n=38) | ||||
| Extensive metabolizer, n | 2 | 8 | 1 | 1 |
| Intermediate metabolizer, n | 3 | 12 | 3 | 1 |
| Slow metabolizer, n | – | 1 | – | – |
| No CYP2B6, n | – | – | – | – |
| Confirmation of the cause of skin rash (n=6) | ||||
| Extensive metabolizer, n | 1 | – | – | – |
| Intermediate metabolizer, n | 1 | – | – | 1 |
| Slow metabolizer, n | 1 | – | – | – |
| No CYP2B6, n | – | – | – | – |
| ADRs besides rash (n=39) | ||||
| Extensive metabolizer, n | 1 | 5 | – | – |
| Intermediate metabolizer, n | 1 | 5 | 2 | 1 |
| Slow metabolizer, n | 2 | 1 | 1 | 1 |
| No CYP2B6, n | – | – | – | – |
| Choice of next ARV (n=20) | ||||
| Extensive metabolizer, n | 1 | 1 | – | – |
| Intermediate metabolizer, n | – | – | – | – |
| Slow metabolizer, n | – | – | – | – |
| No CYP2B6, n | – | – | – | – |
| Total, n | 13 | 33 | 7 | 5 |
| Prevalence (%) | 22.4 | 56.9 | 12.1 | 8.6 |
Note: Five patients had two mutations, and one patient had three mutations.
Abbreviations: ADRs, adverse drug reactions; ARV, antiretroviral drug; CYP2B6, cytochrome P 2B6; HIV, human immunodeficiency virus.